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Abstract
Background: This study aimed to analyze three-dimensional (3D) dosimetric data of conventional two-
dimensional (2D) palliative spinal bone irradiation using different reference points and treatment plans with
respect to the International Commission on Radiation Units and Measurements (ICRU) Report 50.
Methods: Forty-five simulation CT scans of 39 patients previously treated for thoraco-lumbar spinal bone
metastases were used. Three different treatment plans were created: (1) single posterior field plans using
the ICRU reference points (ICRUrps); (2) single posterior field plans using the International Bone
Metastasis Consensus Working Party reference points (IBMCrps); (3) two opposed anterior-posterior
(AP-PA) field plans using the ICRUrps. The intended dose range for planning target volume (PTV) was 90%
to 110% of the prescribed dose for AP-PA field plans. Cumulative dose-volume histograms were generated
for each plan, and minimum, maximum and mean doses to the PTV, medulla spinalis, esophagus and
intestines were analyzed.
Results: The mean percentages of minimum, maximum and mean PTV doses ± standard deviation were,
respectively, 91 ± 1.3%, 108.8 ± 1.3% and 99.7 ± 1.3% in AP-PA field plans; 77.3 ± 2.6%, 122.2 ± 4.3% and
99.8 ± 2.6% in ICRUrp single field plans; and 83.7 ± 3.3%, 133.9 ± 7.1% and 108.8 ± 3.3% in IBMCrp single
field plans. Minimum doses of both single field plans were significantly lower (p < 0.001) while maximum
doses were significantly higher (p < 0.001) than AP-PA field plans. Minimum, maximum and mean doses
were higher in IBMCrp single field plans than in ICRUrp single field plans (p < 0.001). The mean medulla
spinalis doses were lower in AP-PA field plans than single posterior field plans (p < 0.001). Maximum doses
for medulla spinalis were higher than 120% of the prescribed dose in 22 of 45 (49%) IBMCrp single field
plans. Mean esophagus and intestinal doses were higher (p < 0.001) in AP-PA field plans than single field
plans, however, less than 95% of the prescribed dose.
Conclusion: In palliative spinal bone irradiation, 2D conventional single posterior field radiotherapy did
not accomplish the ICRU Report 50 recommendations for PTV dose distribution, while the AP-PA field
plans did achieve the intended dose ranges with a homogenous distribution and reasonable doses to the
medulla spinalis, esophagus and intestines.
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Background
External beam radiotherapy is a well-recognized and effec-
tive modality in the palliation of symptomatic bone
metastases and complication control [1]. Under- or over-
dosing the target volume and dose heterogeneity may not
be major concerns, since many patients treated for pallia-
tive purposes have short survival. However, long term
symptom control associated with bone involvement and
normal tissue complications becomes more vital in cancer
patients with long life-expectancy. Some breast and pros-
tate cancer patients even with spinal cord compression
may live for several years after radiotherapy.
Single posterior field or two opposed anterior-posterior
fields (AP-PA) conventional two-dimensional (2D) radio-
therapy planning without dose volume information is
widely used for palliative spinal bone irradiation using
the International Commission on Radiation Units and
Measurements reference points (ICRUrps) and the Inter-
national Bone Metastasis Consensus Working Party refer-
ence points (IBMCrps) [2,3].
To our knowledge, dosimetric assessment of conventional
2D palliative spinal bone irradiation using three-dimen-
sional (3D) dose information has not been reported. This
study aimed to analyze 3D dosimetric data of palliative
spinal bone irradiation using different reference points
and treatment plans with respect to the International
Commission on Radiation Units and Measurements
(ICRU) Report 50 [2].
Methods
CT simulation
Forty-five simulation CT scans of 39 patients previously
treated for thoraco-lumbar spinal bone metastases were
used for treatment planning. CT scanning was performed
with a 6 detector helical CT (Brilliance, Philips Medical
Systems, Netherlands) and with a 5-mm slice thickness.
Volumes of interest
Target volumes were contoured in corresponding CT slices
(Figure 1). One vertebra above and below the involved
vertebra(e) were included in the clinical target volume
(CTV). However, the upper end-plate of the upper verte-
bra and the lower end-plate of the lower vertebra were not
included in the CTV, to limit the distal and proximal bor-
ders of the treatment fields in the inter-vertebral space. To
determine the planning target volume (PTV), 10 mm was
added to CTV in lateral directions and 5 mm in anterior-
posterior and superior-inferior directions. Treatment
fields were determined by adding 7–10 mm to the PTV
using multi-leaf collimators.
Portions of the esophagus located in thoracic radiother-
apy fields, the intestines located in lumbar radiotherapy
fields and the medulla spinalis in all fields were deline-
ated as critical organs.
Treatment planning
Precise PLAN®2.11 (Elekta, Crawley, UK) treatment plan-
ning system (TPS), which enables 3D conformal radio-
therapy planning, was used for treatment plans. To
calculate the dose distribution of the photon beam, the
TPS uses an irregular field algorithm, for different depths
and field sizes, based on data measures in a phantom. The
algorithm takes into account the inhomogeneity of the
patient's tissue and uses an integration scheme to evaluate
the scatter component of the dose. The dose calculation
grid is set to 2.5 mm.
Three different treatment plans were created (1) single
posterior field treatment plans using ICRUrps; (2) single
posterior field treatment plans using IBMCrps; and (3)
two opposed anterior-posterior (AP-PA) field plans using
ICRUrps.
The ICRUrp was defined as the center of the PTV, the IBM-
Crp was defined as the mid-vertebral body point in the
central plane, and the prescription dose was normalized
to these points (Figure 1). Dose distributions of treatment
plans in one case are shown in Figure 2.
The nominal prescribed dose was 2000 cGy in 5 fractions
using 6-MV photons for posterior fields and 18-MV for
anterior fields. In AP-PA field plans, beam weights were
used as 1 and 1.5–2 in AP and PA fields, while assuring the
intended dose range of 90% to 110% of the prescribed
dose for the PTV. No dose constraint was used in single
posterior field plans.
Cumulative dose-volume histograms (DVH) were gener-
ated for each plan, and minimum, maximum and mean
doses to the PTV, medulla spinalis, esophagus and intes-
tines were calculated for both single posterior fields and
AP-PA field plans.
Cumulative dose-volume histograms of treatment plans
in one case for PTV and medulla spinalis are shown in Fig-
ure 3.
Statistical analysis
The mean, minimum and maximum dose levels were
compared using the Paired-Samples T test for parametric
data on the PTV and medulla spinalis and the Wilcoxon
test for non-parametric data on the esophagus and intes-
tines. P-values of less than 0.05 were considered statisti-Journal of Experimental & Clinical Cancer Research 2009, 28:2 http://www.jeccr.com/content/28/1/2
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Target volumes and reference points Figure 1
Target volumes and reference points. Clinical target volume (CTV), (pink line); planning target volume (PTV), (dark-blue 
line); ICRUrp, the International Commission on Radiation Units and Measurements reference point; IBMCrp, the International 
Bone Metastasis Consensus Working Party reference point.Journal of Experimental & Clinical Cancer Research 2009, 28:2 http://www.jeccr.com/content/28/1/2
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cally significant. Values are expressed as mean (range) ±
standard deviation (SD).
Results
Dose ranges of the PTVs for all plans are shown in Table
1. AP-PA field plans achieved the intended dose ranges
and homogeneity for PTVs, unlike the single posterior
field plans. Minimum doses of both single posterior field
plans were significantly lower (p < 0.001) while maxi-
mum doses were significantly higher (p < 0.001) than AP-
PA field plans. Minimum, maximum and mean doses
were higher in IBMCrp single field plans with an increased
dose heterogeneity than in ICRUrp single field plans (p <
0.001).
The mean depth of the PTV from skin surface in the cen-
tral plane was 9.8 (7.4–13.5) ± 1.1 cm and the mean
patient thickness was 22.1 (14.4–29.1) ± 3.7 cm. Only in
two plans were the ICRUrps and IBMCrps located at the
same sites, which were in the mid-vertebral body. Of 45
ICRUrps, 35 were located on the medulla spinalis behind
the vertebral body and 8 were located in the posterior 1/3
of the vertebral body. None of the ICRUrps were located
in the anterior half of the vertebral body or anterior to the
vertebral body.
The mean dose, expressed as percentages of the prescribed
dose, to the portion of the esophagus in the thoracic radi-
otherapy fields was 78.6% (70–85%) ± 4.1% in the
ICRUrp single field plans, 84.6% (74–92%) ± 5.5% in the
IBMCrp single field plans and 94.5% (87–99%) ± 3.1% in
the AP-PA field plans. The mean dose to the intestines
located in the lumbar radiotherapy fields was 66.2% (58–
78%) ± 5.1% in the ICRUrp single field plans, 73.1% (64–
88%) ± 6.2% in the IBMCrp single field plans and 90.8%
(82–99%) ± 3.7% in the AP-PA fields plans. The mean
doses to the esophagus and intestines were higher in the
AP-PA field plans than in the single posterior field plans
(p < 0.001).
Dose ranges to the medulla spinalis for all plans are
shown in Table 2. The mean doses to the medulla spinalis
were lower in the AP-PA field plans than in the single pos-
terior field plans (p < 0.001).In all IBMCrp single field
Dose distributions in one case for ICRUrp single field plan (A), IBMCrp single field plan (B) and two opposed anterior-poste- rior field plan (C) Figure 2
Dose distributions in one case for ICRUrp single field plan (A), IBMCrp single field plan (B) and two opposed 
anterior-posterior field plan (C). ICRUrp, the International Commission on Radiation Units and Measurements reference 
point; IBMCrp, the International Bone Metastasis Consensus Working Party reference point. The isodose lines are shown as 
follows: 75% (blue), 80% (yellow), 90% (dark blue), 95% (red), 100 (pink), 110% (green), 115% (orange).Journal of Experimental & Clinical Cancer Research 2009, 28:2 http://www.jeccr.com/content/28/1/2
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plans, maximum doses to the medulla spinalis were
greater than 115% of the prescribed dose and in 22 of 45
(49%) plans the maximum doses were greater than 120%
of the prescribed dose. In only 4 ICRUrp single field plans
did the medulla spinalis receive a dose greater than 115%
of the prescribed dose. In the AP-PA field plans, none of
the doses to the medulla spinalis exceeded 106% of pre-
scribed dose.
Discussion
The results of the present study showed that neither IBM-
Crp nor the ICRUrp single posterior field plans accom-
Cumulative dose-volume histograms of one case for planning target volume (PTV) (dark-blue line) and medulla spinalis (red  line) in single field plan using the International Commission on Radiation Units and Measurements reference point (circles), in  single field plan using the International Bone Metastasis Consensus Working Party reference point (squares) and two opposed  anterior-posterior field plan (triangles) Figure 3
Cumulative dose-volume histograms of one case for planning target volume (PTV) (dark-blue line) and 
medulla spinalis (red line) in single field plan using the International Commission on Radiation Units and Meas-
urements reference point (circles), in single field plan using the International Bone Metastasis Consensus 
Working Party reference point (squares) and two opposed anterior-posterior field plan (triangles).Journal of Experimental & Clinical Cancer Research 2009, 28:2 http://www.jeccr.com/content/28/1/2
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plished the ICRU Report 50 recommendations for dose
distribution, while the AP-PA field plans achieved the
intended dose ranges and homogeneity.
The ICRU Report 50 recommends selecting a reference
point that is clinically relevant and representative of the
dose distribution throughout the PTV, where the dose can
be accurately determined and where there is no large dose
gradient [2]. The point located at the center or central part
of the PTV generally fulfills these requirements and is rec-
ommended as the ICRU reference point (ICRUrp). While
a homogeneous dose within 95% to 107% of the pre-
scribed dose is recommended for the target volume, a var-
iation of ± 10% from the prescribed dose is widely used in
clinical practice and was used in the present study for AP-
PA field plans [2].
Thoracic and lumbar spinal irradiation is performed
either with a single posterior field or two opposed AP-PA
fields [4]. The International Bone Metastasis Consensus
Working Party recommends dose prescriptions to the
mid-vertebral body for single-posterior fields and includ-
ing at least one vertebral body above and below the
involved vertebra(e) in the treatment volumes [3]. How-
ever, these recommendations are not supported with dosi-
metric data or treatment outcomes.
Radiotherapy planning and delivery, and dose distribu-
tion may affect treatment outcome by dose coverage and
dose heterogeneity in the target volume. Although several
studies investigated optimal radiotherapy fractionation,
the dose-volume effect on radiotherapy outcome, in terms
of pain relief and duration of response, has not been eval-
uated [5-13]. Furthermore, higher re-treatment rates have
been reported in single-fraction palliative radiotherapy
than in multifraction radiotherapy [12-14]. The relation
between higher re-treatment rates and physician bias, pri-
mary site, pain severity and duration of symptoms has
been evaluated, but the relation between high re-treat-
ment rates and dose coverage has not been investigated.
Studies investigating the relationship between radiother-
apy technique and treatment outcome would provide
important information, particularly for patients with long
life-expectancies.
Dose heterogeneity may become vitally important in
patients with long life expectancies. Minimum target vol-
ume doses as low as 70% of the prescribed dose may
diminish treatment success, while maximum target vol-
ume doses reaching as high as 130% of the prescribed
dose may cause serious normal-tissue side effects in such
patients. In the present study, the mean minimum dose
for PTV in the ICRUrp single field plans was 77.3% (72–
81%) ± 2.6% of the prescribed dose, and the mean maxi-
mum dose for PTV in the IBMCrp single field plans was
133.9% (115–147%) ± 7.1% of the prescribed dose.
When the medulla spinalis doses were assed, maximum
doses were higher than 120% of the prescribed dose in 22
of 45 (49%) IBMCrp single field plans but lower than
106% of prescribed dose in all AP-PA field plans. When
the dose distribution to the esophagus and intestines were
evaluated, mean doses were higher in the AP-PA field
plans than the single field plans, but less than 95% of the
prescribed dose.
Table 1: The mean percentages of minimum, maximum and mean planning target volume (PTV) doses ± standard deviation for all 
plans
Mean dose (range) % ± SD
Single field-ICRUrp Single field-IBMCrp Two opposed fields
Minimums 77.3 (72–81) ± 2.6 83.7 (74–89) ± 3.3 91 (90–95) ± 1.3
Maximums 122.2 (114–130) ± 4.3 133.9 (115–147) ± 7.1 108.8 (104–110) ± 1.3
Means 99.8 (94–107) ± 2.6 108.8 (95–116) ± 3.3 99.7(97–102) ± 1.3
ICRUrp, the International Commission on Radiation Units and Measurements reference point; IBMCrp, the International Bone Metastasis 
Consensus Working Party reference point; SD, standard deviation.
Table 2: The mean percentages of minimum, maximum and mean medulla spinalis doses ± standard deviation for all plans
Mean dose (range) % ± SD
Single field-ICRUrp Single field-IBMCrp Two opposed fields
Minimums 94.2 (85–102) ± 3.0 103.4 (96–109) ± 3.3 96.2 (94–101) ± 1.5
Maximums 108.8 (101–118) ± 3.6 120.1 (115–129) ± 3.5 103.2 (101–106) ± 1.4
Means 102 (95–112) ± 3.1 112.7 (107–117) ± 2.3 100.3 (98–104) ± 1.3
ICRUrp, the International Commission on Radiation Units and Measurements reference point; IBMCrp, the International Bone Metastasis 
Consensus Working Party reference point; SD, standard deviation.Publish with BioMed Central    and   every 
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Conclusion
In palliative spinal bone irradiation, 2D conventional sin-
gle posterior field radiotherapy did not accomplish the
ICRU Report 50 recommendations for PTV dose distribu-
tion, however, two opposed AP-PA field treatment plans
did achieve the intended dose ranges with a homogenous
dose distribution and reasonable doses to the medulla
spinalis, esophagus and intestines.
In patients with long life-expectancies, care must be taken
to obtain a homogenous dose distribution throughout the
target volume and conformal treatment plans rather than
single field treatment plans should be considered in these
patients.
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